In 2011 this blog was listed as one of the top 10 blog in pharma technical information it is popular amongst the pharmacists and pharma industry professionals. We have published very important and very useful information for pharma industry professionals.

Sunday, August 8, 2010

TESTING FOR ADVENTITIOUS AGENTS CELL PROPERTIES Presence of Residual Cells Residual Cellular DNA General Safety Test

TESTING FOR ADVENTITIOUS AGENTS CELL PROPERTIES IN VIRAL VACCINE PRODUCTION.

For a vaccine it is required that the final finished product meets the requirements of freedom from adventitious agents , you may be aware of recent developments on rota virus vaccines (rotarix vaccine) was found to contain DNA fragments , but later on after a detailed study rotarix vaccine was declared safe.

We are trying to provide our readers , a topic wise information about viral vaccine manufacturing quality assurance and quality controlling requirements, and today's topic we have chosen is Testing Adventitious Agents In Viral Vaccines during production.


A. TESTING FOR ADVENTITIOUS AGENTS
B. TESTING OF CELL PROPERTIES
c.OTHER TESTS LIKE
1. Testing for the Presence of Residual Cells
2. Testing for Residual Cellular DNA
3. General Safety Test (GST)

A.ADVENTITIOUS AGENT: A microorganism (including bacteria, fungi, mycoplasma/spiroplasma, mycobacteria, rickettsia, viruses, protozoa, parasites, TSE agent) that is inadvertently introduced into the production of a biological product.

1. In Vivo Tests
a. Adult Mice
b. Suckling Mice
c. Guinea Pigs
d. Rabbits
e. Embryonated Chicken Eggs
f. Antibody Production Tests

2. In Vitro Tests for Viruses

a. Cell Culture Safety Tests
* Human Diploid Cells
* Monkey Kidney Cell Line (usually Vero cells)
b. Transmission Electron Microscopy (TEM)
c. Biochemical Tests for Retroviruses
d. Infectivity Tests for Retroviruses
e. PCR or Other Specific In Vitro Tests
f. Sourcing and Testing of Bovine-Derived Materials
g. Testing of Porcine-Derived Reagents
3. In Vitro Tests for Non-Viral Agents
a. Mycoplasma/Spiroplasm
b. Bacterial and Fungal Sterilit
c. Mycobacteria Testing

B. TESTING OF CELL PROPERTIES
1. Tests for Tumorigenicity
2. Testing for Oncogenicity
3. Identity Testing of Cell Substrates
4. Testing for Genetic Stability

C. OTHER TESTS

1. Testing for the Presence of Residual Cells
2. Testing for Residual Cellular DNA
3. General Safety Test (GST)

For a vaccine to be considered free of a contaminant, your assay should demonstrate, at a predefined level of sensitivity, that a certain quantity of the substance is free of that contaminant.
Assurance that virus vaccines are free of adventitious agents is a critical component of meeting the 21 CFR 610.13 requirement for purity. Cultures must be tested for the presence of detectable microbial agents and tests necessary to assure the safety and purity of the product may be required (21 CFR 610.18).

Biological starting materials being used for producing virus vaccines should be characterized sufficiently to ensure that they do not contaminate the final viccine product with extraneous infectious organisms, such as bacteria, fungi, cultivatable and non-cultivatable mycoplasmas and spiroplasma, mycobacteria, viruses, and the agent(s) responsible for transmissible spongiform encephalopathies (TSEs).

Alternatively, a validated process that is known to remove a contaminant to a defined level may be used to demonstrate the absence of that contaminant. If an adventitious agent is known to be present in your cell substrate or viral seed, then you should demonstrate that your production process is sufficiently robust to eliminate or inactivate the agent with an appropriate margin of safety. You should avoid exposure of your product to agents that are known to be infectious for humans (other than the vaccine virus) and/or to agents for which there are no appropriately sensitive validated testing procedures (such as TSEs). You should have appropriate and sufficient controls in place to assure that such exposures do not occur.

Coming article will cover topics on testing of cell substrates, control cell cultures, viral seeds, and vaccine harvests. When cell substrates are tested, generally, a preparation at 10 rest to 7 cells/mL (or when appropriate, cell lysate from an equivalent number of cells in culture medium) is used, with the indicated volumes. When viral seeds or vaccine harvests are tested, the tests are performed either at the indicated volumes or dose-equivalents. When viral seeds and vaccine harvests are tested, it is often necessary to neutralize the virus prior to inoculation. If the vaccine virus needs to be neutralized in order to perform a valid test, the source of the antiserum and its influence on test results should be considered. In general, antiserum used for neutralization should not be of human or simian origin or from the same cell type used for production of the vaccine virus.

The most appropriate tests for adventitious agents in a given vaccine will vary depending on a variety of factors, including the origin of the cell substrate and its history. We encourage manufacturers to consult with us in selecting the appropriate tests. See Section III for additional information on factors to take into account in selecting appropriate tests.
For each of the tests for adventitious agent alternatives such as those recommended by the World Health Organization (WHO) or the European Pharmacopoeia (EP) or different inoculation strategies for testing cell bank lysates and viral harvests are also considered by US FDA when justified in the context of the entire testing program.


No comments:


What is 21 CFR Part 11, US FDA guidelines requirements of FDA compliance and CFR 21 Part 11.

What is a Site Master file of a pharmaceutical company

What is Generic Drug

What is Reference Listed Drug  ? ( RLD )

What is Pharmaceutical Equivalents

What is Pharmaceutical Alternatives

What is Therapeutic Equivalents

What are Post Market studies

Why a drug is bound to protein, What is protein binding?  What is drug absorption , distribution ?

Do Physical properties contribute to drug activity.

What is drug receptor , How a drug resistance occurs

Mechanism of drug resistance

What is drug interaction

Drug interaction, and its examples

What is first pass metabolism of a drug

What is What is 510(k) Clearances ?

What is 510(k) Clearances,

Premarket Notification for medical devices - PMN or 510(k)

What is a drug interaction

Examples of drug interactions


Antibiotic Definition and classification


Antibiotic Resistance and Antibiotic resistance mechanism

Antioxidants food supplements

Vitamin D Details on FDA cautions on accurate dosage of Vitamin D


What is an antibody? what is monoclonal and polyclonal antibodies?

Terminologies In vaccine Production

Multi stage testing of Virus vaccine production

Testing of vaccines at different stages of production

TESTING FOR ADVENTITIOUS AGENTS CELL PROPERTIES IN VIRAL VACCINE PRODUCTION

Enzyme linked immunosorbent assay ELISA

Raido Immuno assay

http://whoguideline.blogspot.com/2010/04/terminalogy-and-their-explanations.html

Pharmaceutical Aseptic Manufacturing Process Terms , Terminology and Definitions.

http://whoguideline.blogspot.com/2010/02/pharmaceutical-aseptic-manufacturing.html

Here are some articles which will be useful for you in further understanding of aspects of sterile dosage form manufacturing and regulatory affairs and good manufacturing practice in

pharmaceutical industry

Pharmaceutical Validation

Types of validations in pharmaceutical manufacturing


Requirements of documents for validation of sterilisation process

How to investigate OOS out of specification results

Determination of Phenol coefficient of a disinfectant

Sterility testing

Clean Room Classification

Time limitations in sterile pharmaceuticals processing

Aspects of validation of manufacturing process in sterile pharmaceuticals

Clinical Trials

Requirements of US FDA Inspections of Clinical Investigators of Clinical Trials

PROCEDURE OF AN INSPECTIONS OF CLINICAL TRIAL INVESTIGATOR BY US FDA HOW ARE CLINICAL INVESTIGATOR INSPECTIONS CONDUCTED?

US FDA INSPECTION OF CLINICAL INVESTIGATORS OUT OF UNITED STATES OF AMERICA

REPORTS AFTER AN INSPECTION OF A INVESTIGAOTR OF CLINICAL TRIALS

Controlling Pyrogens in injectable dosage forms

Media fill run process simulation aspects Validation of Aseptic Process and Sterilisation

New Drug Application (NDA) how to make a New Drug Application (NDA) to US FDA

Abbreviated New Drug Application (ANDA) What is ANDA , detailed information about ANDA preparation and submission to US FDA

How to make Investigational New Drug (IND) Application to US FDA

Drug applications submission to us fda Over the counter Drugs OTC drugs

BIOAVAILABILITY AND BIOEQUIVALENCE REQUIREMENTS

Electronic record in pharmaceutical manufacturing industry

Good manufacturing practice in pharmaceutical industry

Pharmaceutical industry pharmaceutical companies and FDA latest updates